CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab

Background The mammalian target of rapamycin (mTOR) signaling pathway plays a pivotal role in numerous cellular processes involving growth, proliferation and survival. The purpose of this study was to investigate the anti-tumoral effect of the mTOR inhibitor (mTORi) CCI-779 in HNSCC cell lines and i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Niehr, Franziska (VerfasserIn) , Weichert, Wilko (VerfasserIn) , Stenzinger, Albrecht (VerfasserIn)
Dokumenttyp:	Article (Journal)
Sprache:	Englisch
Veröffentlicht:	1 April 2015
In:	Journal of translational medicine Year: 2015, Jahrgang: 13
ISSN:	1479-5876
DOI:	10.1186/s12967-015-0456-6
Online-Zugang:	Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1186/s12967-015-0456-6 Verlag, kostenfrei, Volltext: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389307/
Verfasserangaben:	Franziska Niehr, Wilko Weichert, Albrecht Stenzinger, Volker Budach, Ingeborg Tinhofer

CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab von Niehr, Franziska (VerfasserIn) , Weichert, Wilko (VerfasserIn) , Stenzinger, Albrecht (VerfasserIn) ,

BioMed Central 2015

Resolving-System, kostenfrei, Volltext

Article (Journal) Book/Monograph Online Resource

CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab

CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab von Niehr, Franziska (VerfasserIn) , Weichert, Wilko (VerfasserIn) , Stenzinger, Albrecht (VerfasserIn) ,

Ähnliche Einträge